Navigation Links
AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
Date:5/2/2013

System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps.  AcelRx has announced results from two Phase 3 clinical trials for the NanoTab System, and a third Phase 3 study has completed enrollment, with data expected in the second quarter of 2013. A New Drug Application submission is planned for the third quarter of 2013. AcelRx recently announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the release of the NanoTab System and ARX -04 top-line clinical trial data, the release and anticipated timing of additional NanoTab System clinical trial data, the potential submission of an NDA for NanoTab System and the timing thereof, therapeutic and commercial potential of NanoTab System and the anticipated timing and therapeutic and commercial potential of other AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forwar
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
2. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
3. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. AcelRx Pharmaceuticals Provides Clinical Trial Updates
7. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
8. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
10. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
11. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Mass. , July 22, 2014  Decision ... audited multiple sclerosis (MS) patients currently treated ... Tecfidera have ever experienced flushing and/or gastrointestinal ... Tecfidera-treated patients are currently experiencing these side ... the effective medical management of such events. ...
(Date:7/22/2014)... ALBANY, New York , July 22, 2014 ... published by Transparency Market Research "Process Spectroscopy Market (Technology Types ... infrared (FT-IR) spectroscopy) Market - Global Industry Analysis, Size, Share, ... valued at USD 714.5 million in 2012 and is expected ... 2019. North America was ...
(Date:7/22/2014)... -- Research and Markets  has announced the addition ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... monitor, and assess medical conditions, diseases, or infections usually ... earlier and more targeted treatment. These tests are minimally ... This kind of diagnostics provides early detection of diseases ...
Breaking Medicine Technology:Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3
... Millennium: The Takeda Oncology,Company today reported ... III clinical trials of VELCADE based combinations ... previously untreated,multiple myeloma (MM). Prolonged progression-free survival ... and dexamethasone (VcD) with vincristine,adriamycin and dexamethasone ...
... 8 Alexion Pharmaceuticals,Inc. (Nasdaq: ... AEGIS, an open-label,registration study examining Soliris(R) (eculizumab) ... (PNH). The pre-specified,primary efficacy endpoint of change ... reduction (P<0.001). Key secondary endpoints including fatigue,(P<0.001) ...
Cached Medicine Technology:Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 2Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 3Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 4Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 5Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 6Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 7Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 8
(Date:7/22/2014)... 2014 The Latin America Drilling fluid and ... and completion fluid market in Latin America with analysis and ... in Latin America is estimated to grow from around $0.93 ... CAGR of 9.2%, for the given period. , Browse through ... fluid Market Report, to get an idea of the in-depth ...
(Date:7/22/2014)... The donation from the Edusei Foundation was greatly appreciated by ... of strategic engineering, such assistance tends to etch good memories ... It provided a sense of family to them, which the ... Foundation donated various amounts of; milk, soap, frytol, sugar, ... Government of Ghana established the Kumasi Children’s Home in 1965 ...
(Date:7/22/2014)... The Middle East Drilling fluid and Completion fluid Market ... market in Middle East with analysis and forecast of revenue. ... is estimated to grow from around $560 million in 2013 ... for the given period. , Browse through the TOC of ... to get an idea of the in-depth analysis provided. This ...
(Date:7/22/2014)... 22, 2014 According to ... Market Research “Circulating Circulating Tumor Cells (CTCs) ... (Filtration, Centrifugation and Immunological & Immunomagnetic Methods) ... Optical Methods) and Applications: Prostate Cancer, Breast ... Industry Analysis, Size, Share, Growth, Trends and ...
(Date:7/22/2014)... Carlsbad, CA (PRWEB) July 22, 2014 ... 0% financing for 24 months on all models during ... 18th-28th. , Please visit http://www.d1spas.com/financing for ... leader in hydrotherapy, Dimension One Spas offers a wide ... your fingertips including lights, fountains, waterfalls, music, customizable massage, ...
Breaking Medicine News(10 mins):Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 6Health News:Edusei Foundation Donates Food and Needed Items to Kumasi Children’s Home in Ashanti Region of Ghana 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020 2Health News:Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020 3Health News:Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020 4
... a recent research, drinking cola can lead to brittle bones ... the carbonated drink women consumed, the weaker// were their bones. ... advised not to drink too much of cola. The phosphoric ... drinks, is assumed to be responsible for the problem. ...
... Health Organization (WHO) for the first time issued Global Air ... air pollution that kills 2 million// people each year with ... ,The WHO appealed to governments to enhance air quality in ... in Manila revealed that almost 3,00,000 lives could be saved ...
... to cause deaths in women in developing countries is ... of deaths caused// because of uncontrolled bleeding following childbirth ... and studies conducted by researchers from the University of ... Institutes of Health . The studies have come to ...
... on the Indonesian resort island of Bali were in stable ... case, but so far they are stable," Wayan Sutarga, director ... Denpasar, told DPA., ,"We are still examining the babies, ... said, adding that in medical terms the girls are thoraco ...
... National Osteoporosis Foundation has estimated that nearly 55 percent ... osteoporosis, a disease of porous and brittle bones// that ... beverage among Americans has been found to contribute to ... studies conducted by Katherine Tucker, PhD, director of the ...
... C has become the scourge of multitude of Queenslanders, with ... disease//, underlining the importance of early medical intervention in the ... by a virus that targets the liver, which can also ... rolled out figures that show the alarming rise of Hepatitis ...
Cached Medicine News:Health News:Cola increases risk of Osteoporosis!! 2Health News:A Safe Drug For Safe Delivery 2Health News:Consumption of Colas Increase Risk of Osteoporosis in Older Women 2Health News:Consumption of Colas Increase Risk of Osteoporosis in Older Women 3
... not restricted to small central fields, ... are full field capable, all encompassing ... you'll ever need to ensure the ... They also include the most important ...
... an innovative device designed to be a ... abdominal aortic aneurysms (AAA). It is constructed ... an outer self-expanding Nitinol support structure to ... The function of the endoprosthesis is to ...
... to remove a cast from an arm or ... patients are cut or burned by the cast ... professionals to remove any cast with confidence. This ... cuts and burns from the cast saw and ...
... creation of a vascular access, a correctly ... the utmost importance in many vascular procedures. ... seeking a high-precision tunneling instrument. The unique ... twisting or kinking for more accurate graft ...
Medicine Products: